Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma

Shijubo, Noriharu; Honda, Yasuhiro; Fujishima, Takuya; Takahashi, Hiroki; Kodama, Taku; Kuroki, Yuichiro; Akino, Tatsuaki; Abe, Shinya

doi:10.1183/09031936.95.08030403

Cited by 33 publications

(19 citation statements)

References 24 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O'Reilly et al (16) (31,32). Furthermore, Shijubo et al (33,34) found that 27 of 67 patients with lung adenocarcinomas had high levels of SP-A in their pleural effusions, whereas patients with adenocarcinomas originating from different primary sites, other histologic types of lung cancers, and tuberculosis had low levels, suggesting that detection of SP-A in malignant effusions might help distinguish primary lung adenocarcinoma from other adenocarcinomas of miscellaneous origins. However, Fujita et al (35), using both immunohistochemical analysis and reverse transcriptase-PCR, detected SP-A expression in only 1 of 16 lung cancer cell lines, 6 of which were adenocarcinomas.…”

Section: Discussionmentioning

confidence: 99%

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Jiang¹,

Caraway²,

Bekele

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: The present study was conducted to determine clinical relevance of surfactant protein A (SP-A) genetic aberrations in early-stage non^small cell lung cancer (NSCLC). Experimental Design: To determine whether SP-A aberrations are lung cancer^specific and indicate smoking-related damage, tricolor fluorescence in situ hybridization with SP-A and PTEN probes was done on touch imprints from the lung tumors obtained prospectively from 28 patients with primary NSCLC. To further define the clinical relevance of SP-A aberrations, fluorescence in situ hybridization was done on both tumor cells and adjacent bronchial tissue cells from paraffin-embeddedtissueblocksfrom130 patientsNSCLC for whomwehadfollow-upinformation. Results: SP-A was deleted from 89% of cancer tissues and the deletion was related to the smoking status of patients (P < 0.001). PTEN was deleted from 16% in the cancer tissues and the deletion was not related to the smoking status of patients (P > 0.05). In the cells isolated from paraffin-embedded tissue blocks, SP-A was deleted from 87% of the carcinoma tissues and 32% of the adjacent normal-appearing bronchial tissues. SP-A deletions in tumors and adjacent normal-appearing bronchial tissues were associated with increases in the risk of disease relapse (P = 0.0035 and P < 0.001, respectively). SP-A deletions in the bronchial epithelium were the strongest prognostic indicators of disease-specific survival (P = 0.025). Conclusions: Deletions of the SP-A gene are specific genomic aberrations in bronchial epithelial cells adjacent to and within NSCLC, and are associated with tumor progression and a history of smoking. SP-A deletions might be a useful biomarker to identify poor prognoses in patients with NSCLC who might therefore benefit from adjuvant treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Jiang¹,

Caraway²,

Bekele

et al. 2005

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…In some cases differentiating between reactive mesothelial cells, mesothelioma, and adenocarcinoma can be problematic. Tumour markers such as carcinoembryonic antigen (CEA), Leu-1, and mucin, may be helpful in establishing the diagnosis, as they are frequently positive in adenocarcinomas (50-90%) but rarely seen with mesothelial cells or mesothelioma (0-10%) [61][62][63][64][65][66][67][68][69][70][71].…”

Section: Diagnostic Thoracentesismentioning

confidence: 99%

Management of malignant pleural effusions

et al. 2001

View full text Add to dashboard Cite

“…Several studies based on different approaches including, reverse transcriptase PCR, immunoblot analysis, ELISA and immunohistochemical analysis have been carried out to study alterations of SP-A in lung cancer (122)(123)(124)(125)(126)(127)(128), while there is a single study (129) that has reported usefulness of SP-D as a diagnostic marker for lung cancer. Immunohistochemical detection of SP-A in lungs (130) and pleural effusions (131) has been reported to be useful for differential diagnosis of lung cancer from metastatic carcinomas to lung and pleural mesotheliomas.…”

Section: Methylation Signatures In Spsmentioning

confidence: 99%

Surfactant protein DNA methylation: A new entrant in the field of lung cancer diagnostics? (Review)

Vaid

Floros²

1994

Oncol Rep

View full text Add to dashboard Cite

Abstract. Lung cancer is a major cause of cancer-related mortality in both men and women. A 5-year survival of lung cancer patients is only 15% with a negative correlation between progressively advanced lung cancer stage and a 5-year survival period. The only chance for cure is surgical resection if done at the early stage of the disease. Therefore, an early diagnosis and a better prediction of prognosis could decrease mortality. An early diagnosis could provide the opportunity for a therapeutic intervention early in the course of the disease. Genetic alterations in the cancer genome include aneuploidy, deletions and amplifications of chromosomal regions, loss of heterozygosity (LOH), microsatellite alterations, point mutations and aberrant promoter methylation. Of the various types of genetic alterations (i.e. gene amplifications, allele deletions, point mutations or deletions and methylation) reported in different tumor types, aberrant promoter methylation of genes is recent and is the focus of the present review. Specifically, we will briefly review the role of promoter methylation in various malignancies and then focus on lung cancer diagnosis and promoter gene methylation with emphasis on the methylation status of genes of the innate host defense, namely the surfactant proteins A and D. Lung cancer prevalence and current statusLung cancer is a major cause of cancer-related mortality in both men and women in industrialized countries and causes more deaths than colorectal, breast and prostate cancer combined (1,2). The overall annual incidence and mortality rate of lung cancer has been estimated to be ~104 million new cases per year and 921,000 deaths in the world, with the highest rates currently observed in Europe and North America (3,4). The incidence and mortality rates are higher for men than for women. However, lung cancer mortality has increased markedly among women since 1960, following an increased prevalence of smoking (5). A high degree of correlation between smoking and lung cancer has been observed. Smoking accounts for 80% of the attributed risk among men and for 45% of the cases among women (6).The 5-year survival of lung cancer patients is only 15%, which is much lower than the survival rate of colorectal (41%) and breast (67%) cancers. This is largely due to the fact that three quarters of lung cancer patients are diagnosed when their disease has spread regionally or distantly (7). There are studies on negative correlation between a 5-year survival period and lung cancer stage (as per TNM classification, where T is characteristic of primary tumor, N is regional lymph node involvement and M is metastasis). A 5-year survival period has been reported as high as 60-70% following resection of stage I lung cancer, while a 5-year survival rate of lung cancer as low as 8-13% has been observed if treatment starts at stages III-IV (8). At present, the only chance of cure is surgical resection at the early stage of the disease, with better prognosis for small tumors compared to larger ones. Thus, an ea...

show abstract

Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma

Cited by 33 publications

References 24 publications

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Surfactant Protein A Gene Deletion and Prognostics for Patients with Stage I Non–Small Cell Lung Cancer

Management of malignant pleural effusions

Surfactant protein DNA methylation: A new entrant in the field of lung cancer diagnostics? (Review)

Contact Info

Product

Resources

About